SubscribeSign In

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.

https://www.wsj.com/articles/illumina-ceo-francis-desouza-resigns-89c38eec

Illumina CEO Francis deSouza Resigns Amid Regulatory Hurdles, Proxy Fight

Activist investor Carl Icahn has signaled he wants former CEO Jay Flatley to return to gene-sequencing test maker

By Peter Loftus
Francis deSouza will remain as an adviser at Illumina until the end of next month. Photo: Victor J. Blue/Bloomberg News

Francis deSouza resigned as Illumina’s chief executive as the gene-sequencing test maker fights regulators over a $7 billion deal for cancer-test developer Grail and after a proxy battle with activist investor Carl Icahn. 

Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Continue reading your article with
a WSJ subscription

Subscribe Now

Already a subscriber? Sign In

Sponsored Offers

Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.